Somewhat Positive Media Coverage Somewhat Unlikely to Impact Aratana Therapeutics (PETX) Share Price
Press coverage about Aratana Therapeutics (NASDAQ:PETX) has trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aratana Therapeutics earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.7568183776025 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
PETX has been the topic of a number of recent analyst reports. Zacks Investment Research lowered Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, November 18th. HC Wainwright set a $10.00 price objective on Aratana Therapeutics and gave the stock a “buy” rating in a research note on Thursday, December 21st. Jefferies Group reiterated a “buy” rating and issued a $8.00 price objective on shares of Aratana Therapeutics in a research note on Friday, November 3rd. ValuEngine lowered Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Finally, CL King initiated coverage on Aratana Therapeutics in a research note on Wednesday, December 27th. They issued a “neutral” rating on the stock. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $8.55.
Shares of Aratana Therapeutics (NASDAQ:PETX) traded down $0.14 on Friday, reaching $4.18. The company had a trading volume of 215,714 shares, compared to its average volume of 494,504. Aratana Therapeutics has a 1 year low of $3.91 and a 1 year high of $7.67. The company has a quick ratio of 3.08, a current ratio of 3.42 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $173.91, a price-to-earnings ratio of -2.88 and a beta of 3.06.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-aratana-therapeutics-petx-share-price/1872810.html.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.